IDEAYA Biosciences, Inc. (IDYA)
| Market Cap | 2.21B |
| Revenue (ttm) | 3.92M |
| Net Income (ttm) | -178.12M |
| Shares Out | 86.43M |
| EPS (ttm) | -2.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,763,363 |
| Open | 24.57 |
| Previous Close | 24.79 |
| Day's Range | 24.51 - 26.49 |
| 52-Week Range | 24.48 - 47.74 |
| Beta | 0.80 |
| Analysts | Strong Buy |
| Price Target | 53.67 (+109.57%) |
| Earnings Date | Nov 4, 2024 |
About IDYA
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioa... [Read more]
Financial Performance
In 2023, IDEAYA Biosciences's revenue was $23.39 million, a decrease of -54.08% compared to the previous year's $50.93 million. Losses were -$112.96 million, 92.6% more than in 2022.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price forecast is $53.67, which is an increase of 109.57% from the latest price.
News
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
Independent Data Monitoring Committee (IDMC) recommends move-forward dose in Part 2a of potential registration-enabling trial in 1L HLA-A2-Negative MUM, based on clinical efficacy and safety observed ...
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
Nominated development candidate IDE251, a potential first-in-class KAT6/7 inhibitor IDE251 is targeted to be evaluated in breast and NSCLC with 8p11 amplification, and in the setting of lineage addict...
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
SOUTH SAN FRANCISCO, Calif. , Dec. 11, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap...
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
First patient dosed with combination of IDE161, IDEAYA's investigational, potential first-in-class PARG inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy The IDEAYA-s...
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
IDE892 is a potent and selective MTA-cooperative PRMT5 inhibitor with favorable ADME properties; demonstrating robust MTAP deletion-specific pathway suppression and highly durable antitumor activity i...
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Dec. 6, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape...
Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash
Ideaya Biosciences' stock experienced volatility, with significant movements driven by clinical data releases and a secondary offering, but currently trades near its December levels. Ideaya's lead can...
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
SOUTH SAN FRANCISCO, Calif. , Dec. 2, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape...
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial launc...
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap...
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
Nominated IDE034 (BCG034) as a development candidate, a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) Option exercised for an exclusive worldwide license...
Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
BEIJING & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Antibody--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of nove...
IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update
Enrollment in darovasertib + crizotinib 1L HLA-A2+ MUM potential Ph2/3 registration-enabling trial is ahead of schedule and has exceeded 150 patients Successful FDA Type C meeting and targeting initia...
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors
IDE275 (GSK959) development is progressing into First-in-Human Phase 1 clinical trial(s) for the treatment of MSI-High solid tumors, representing IDEAYA's 5th potential first-in-class clinical program...
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024
~33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSCLC patients 9 of 9 responses have confirmed by RECIST 1....
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium
SOUTH SAN FRANCISCO, Calif. , Oct. 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu...
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate
Ideaya Biosciences Inc. IDYA, a precision medicine oncology company, released interim Phase 2 clinical trial data.
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with > 30% tumor shrinkage by product of diameters, and ~...
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
SOUTH SAN FRANCISCO, Calif. , Sept. 22, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap...
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
IDEAYA Biosciences uses synthetic lethality to target genetic vulnerabilities in cancer cells, focusing on MTAP-deleted tumors. IDE397 demonstrated promising Phase 2 results with high response rates i...
IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDA SOUTH SAN FRANCISCO, Calif. , Sept. 18, 20...
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap...
IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Darovasertib achieves triple-digit enrollment in Phase 2/3 trial in 1L HLA-A2*02:01(-) MUM; and >50 patients enrolled in Phase 2 neoadjuvant UM study ASCO 2024 oral presentation of darovasertib in neo...
Generational Group Advises Schuylkill Haven Casket Company and Columbia Caskets Corp. in its sale to Victoriaville & Co.
DALLAS--(BUSINESS WIRE)--Generational Group, a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of its client, Schuylkill Haven Casket Comp...
Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program
BEIJING & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/A...